Irvine, CA—June 28, 2021—Modulim, provider of optical imaging solutions that incorporate its patented spatial frequency domain imaging (SFDI) technology to transform healthcare and help people live healthier, longer lives, announced today that the Korean Intellectual Property Office has granted patent number 10-2251749 to Modulated Imaging Inc. (dba Modulim) for the invention of “efficient modulated imaging.”
“This is exciting news, and will help Modulim protect our IP as we expand globally,” said Charlie Huiner, President and CEO. “We look forward to continued growth.”
Modulim is a privately held medical device company founded by the inventors of SFDI at the University of California Irvine with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Its mission is to deliver transformative optical solutions that help people live healthier, longer lives. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Clarifi Imaging System is an FDA cleared and CE Marked product. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK. Clarifi is a registered trademark of Modulated Imaging (dba Modulim).
VP Sales and Marketing